trending Market Intelligence /marketintelligence/en/news-insights/trending/zbwecfyantfbirjowwsz8q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

MabVax to delist from Nasdaq

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


MabVax to delist from Nasdaq

MabVax Therapeutics Holdings Inc. said it received a delisting determination from Nasdaq Stock Market LLC.

MabVax directors previously decided against planning to regain compliance with the exchange's listing rules.

MabVax was not in compliance with the exchange's listing requirements for stockholders' equity and periodic report filings. MabVax underwent a Securities and Exchange Commission investigation regarding its financial and registration statements.

The San Diego-based biopharmaceutical company will not appeal the decision, and its common stock will be suspended from the Nasdaq Capital Market on July 11.